Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company, has officially announced the record and payment dates for its final dividend for the financial year 2025-26 (FY26). Shareholders can expect a dividend of Rs 5 per equity share.
Important Dates for Sun Pharma FY26 Dividend
The company has set July 7, 2026, as the crucial record date. This date will determine which shareholders are eligible to receive the dividend payout. Following shareholder approval at the upcoming Annual General Meeting (AGM), the dividend payment is slated to be made on or before Friday, August 7, 2026.
The 34th Annual General Meeting of Sun Pharmaceutical Industries is scheduled for Friday, July 31, 2026, at 4:00 PM IST, and will be conducted via video conferencing.
Shareholder Information and Market Reaction
Sun Pharma has advised shareholders to ensure their contact details, including email IDs and addresses, are updated with their Depository Participants for dematerialised shares or with the Company's Registrar and Transfer Agent for physical shares. This ensures timely receipt of the Annual Report, AGM Notice, and dividend credit.
On the announcement day, Sun Pharma shares saw a modest rise of 0.65 percent, closing at Rs 1,798.80. Year-to-date, the stock has climbed 4.56 percent.
Brokerage Insights on Sun Pharma
Brokerage firm JM Financial noted a moderate performance for Sun Pharma in Q4 FY26, with revenue and adjusted profit after tax (PAT) growing 13 percent and 11 percent year-on-year, respectively. However, EBITDA growth remained modest at 3 percent due to factors like lower milestone income and increased investments. Despite the potential for the proposed Organon acquisition to bolster its specialty portfolio, JM Financial downgraded the stock to 'ADD', citing its recent run-up and near-term margin pressures, setting a target price of Rs 2,011.
Conversely, Choice Institutional Equities maintained its 'Buy' rating on Sun Pharma. While marginally revising its FY27 earnings estimate downwards by 1.1 percent, the firm upheld its target price of Rs 2,300, valuing the company at 25 times its FY28E EPS.